期刊文献+

替米沙坦治疗早期糖尿病肾病的效果观察 被引量:6

Effect observation of telmisartan in the treatment of early diabetic nephropathy
下载PDF
导出
摘要 目的探讨替米沙坦治疗早期糖尿病肾病的效果。方法选取2011年5月~2014年5月在本院治疗的70例早期糖尿病肾病患者作为研究对象,随机分为治疗组及对照组,各35例。对照组给予常规治疗,治疗组在对照组的基础上给予替米沙坦治疗。比较两组治疗前后的血糖、平均动脉压(MAP)、24 h尿蛋白排泄率(UAER)、C反应蛋白(CRP)及白介素-6(IL-6)水平。结果两组治疗后的空腹血糖及餐后2 h血糖水平显著低于治疗前,差异有统计学意义(P〈0.05)。两组治疗后的MAP、UAER、CRP及IL-6水平显著低于治疗前,差异有统计学意义(P〈0.05)。治疗组治疗后的MAP、UAER、CRP及IL-6水平显著低于对照组治疗后,差异有统计学意义(P〈0.05)。CRP及IL-6水平与UAER呈正相关,空腹血糖及餐后2 h血糖水平与UAER无显著性相关。结论炎症反应参与糖尿病肾病的发展,替米沙坦可以降低早期糖尿病肾病患者的MAP,减少尿蛋白排出,降低炎症反应,能够防治早期糖尿病肾病。 Objective To explore the effect of telmisartan in the treatment of early diabetic nephropathy(DN). Methods 70 cases of early DN patients from May 2011 to May 2014 in our hospital were selected and randomly divided into the treatment group and the control group,35 cases in each group.The control group was given conventional therapy,the treatment group was given telmisartan on the basis of the control group.The level of blood glucose,mean arterial pressure(MAP),24 hours urinary albumin excretion rate(UAER),C reactive protein(CRP) and interleukin-6(IL-6) in the two groups was compared before and after treatment. Results The level of fasting blood glucose and postprandial 2hours blood glucose after treatment in the two groups was lower than that before treatment,with significant difference(P〈0.05).The level of MAP,UAER,CRP and IL-6 after treatment in the two groups was lower than that before treatment,with significant difference(P〈0.05).The level of MAP,UAER,CRP and IL-6 in the treatment group after treatment was lower than that in the control group after treatment,with significant difference(P〈0.05).The level of CRP and IL-6 were positive correlation with UAER,but the level of fasting blood glucose and postprandial 2 hours blood glucose were not significant correlation with UAER. Conclusion Inflammatory reaction involves in the develepment of DN.Telmisartan can reduce the MAP in patients with early diabetic nephropathy,urinary protein excretion,inflammation,which can prevent and treat early DN.
出处 《中国当代医药》 2016年第4期73-75,共3页 China Modern Medicine
基金 辽宁省辽阳市科技局科技计划项目(200809)
关键词 替米沙坦 糖尿病肾病 效果观察 Telmisartan Diabetic nephropathy Effect observation
  • 相关文献

参考文献16

  • 1张路霞,王海燕.从流行病学的角度探讨我国糖尿病肾病的发病趋势及对策[J].中华内科杂志,2010,49(9):804-805. 被引量:112
  • 2丁小蓉,王荣花.替米沙坦治疗糖尿病合并高血压的临床疗效分析[J].检验医学与临床,2013,10(22):2980-2981. 被引量:8
  • 3Navarro-Gonzalez JF,Mora-Fernandez C,Muros de Fuentes M,et a/.Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy[J].Nat Rev Nephrol, 2011,7(6) :727.
  • 4Navarro JF,Mora C,Maca M,et a/.Inflammatory parame- ters are independently associated with urinary albumin in type 2 diabetes mellitus[J].Am J Kidney Dis,2003,42( 1): 53-61.
  • 5Wada J,Makino H.Inflammation and the pathogenesis ofdiabetic nephropathy[J].C lin Sci (Lond), 2013,124 (3) : 139- 152.
  • 6Kang ES,'Kim HJ, Ahn CW, et a/.Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes[J].Di- abetes Res Clin Pract, 2005,69 ( 2 ) : 151-159.
  • 7Bums KD.Angiotensin ]I and its receptors in the diabetic kidney[J].Am J Kindey Dis, 2000,36 (3) : 449-467.
  • 8Walsh BH,Boylan GB,Livingstone V,et a/.C0rd blood pro- teins and multichannel-electroencephalography in hypoxic- ischemic encephalopathy[J].Pediatr Crit Care Med,2013, 14(6) : 621-630.
  • 9张昱.替米沙坦辅助治疗糖尿病肾病疗效观察[J].湖南中医药大学学报,2013,33(2):31-32. 被引量:7
  • 10Benson SC,Pershadsingh HA, Ho CI,et a/.Identification of telmisartan as a unique angioresin 11 receptor antago- nist with selective PPARgamma-modulating activity [J]. Hypeitention, 2004,43 (5) : 993-1002.

二级参考文献36

  • 1褚瑰丽,贾汝汉,高苹,宋恩峰,陈铖,丁国华.替米沙坦对糖尿病大鼠肾小球表达整合素α3β1的影响[J].中华肾脏病杂志,2005,21(9):543-547. 被引量:7
  • 2王立军,马虹,廖新学,胡雪松,田方,顾海波,郝艳华,蔡乙明,彭龙云,何建桂,曾武涛,冷秀玉.替米沙坦对人血管内皮细胞血管紧张素转换酶-2表达的调节作用研究[J].中国危重病急救医学,2006,18(4):224-228. 被引量:16
  • 3陈铖,贾俊亚,丁国华,梁伟,褚瑰丽,朱吉莉,贾汝汉.替米沙坦对老年糖尿病大鼠足细胞黏附的保护作用[J].中华肾脏病杂志,2007,23(3):172-177. 被引量:7
  • 4Piva R, Belardo G, Santoro MG. NF- kappaB : a stress regulated switch for cell survival [ J ]. Antioxid Redox Signal, 2006,8 (3 - 4) : 478 - 486.
  • 5Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin Ⅱ receptor antagonist with selective PPARgamma-modulating activity [ J ]. Hypertension, 2004,43(5) :993 - 1002.
  • 6Nobuyuki B, Tsutomu N, Michiko M, et al. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy [ J ]. Kidney Int, 2000,58 (4) : 684 - 690.
  • 7Wada T, Yokoyama H, Matsushima K, et al. Monocyte chemoattractant protein-1 :dose it play a role in diabetic nephropathy [J ] ? Nephrol Dial Transplant, 2003,18 : 457 - 459.
  • 8Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients [ J ]. Diabetes, 2005,54 (7) : 2206 - 2211.
  • 9Ha H, Yu MR, Choi YJ,et al. Role 4 high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells[J]. J Am Soc Nephml, 2002, 13: 894 - 902.
  • 10Border WA, Noble ZA. Evidence that TGF--bate should be a therapeutic target in diabetic nephropathy. Kidney Int, 1998,54 (4) : 1390.

共引文献135

同被引文献42

引证文献6

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部